FLT3 and acute myeloid leukemia: A Phase II/III trial (NCT03642236) is evaluating the potential of ibrutinib in combination with conventional chemotherapy (decitabine, aclacinomycin, cytarabine, G-CSF and sorafenib with or without FLT3 inhibitor) to overcome drug-resistance in relapsed or refractory (R/R) FLT3 mutant AML.